Adolor Corporation
Wikipedia on Answers.com:
Top
Adolor Corporation
 |
|
| Type | Public |
|---|---|
| Industry | Pharmaceutical |
| Headquarters | Exton, Pennsylvania, United States |
| Key people | Michael R. Dougherty |
| Revenue |  US$37.4 Million (FY 2009)[1] |
| Operating income |  US$-47.9 Million (FY 2009)[1] |
| Net income | US$-47.9 Million (FY 2009)[1] |
| Total assets | US$91.5 Million (FY 2009)[2] |
| Total equity | US$44.1 Million (FY 2009)[2] |
| Employees | 108[3] |
| Website | www.adolor.com |
Adolor Corporation (NASDAQ: ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of prescription pain management products.
Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.
Adolor’s first approved product in the United States is Entereg, which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Entereg is available for short-term use in hospitals registered under the Entereg Access Support and Education (E.A.S.E.TM) Program. In collaboration with GlaxoSmithKline, the Company launched Entereg in mid-2008.
The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs. Adolor has two lead product candidates in development: Entereg (alvimopan) for the management of the gastrointestinal side effects associated with opioid use; and, Delta opioid receptor agonists for a variety of pain indications. Adolor and GlaxoSmithKline are collaborating in the worldwide development and commercialization of Entereg in multiple indications. The drug is being reviewed by the Food and Drug Administration, and the process is expected to be completed in May 2008.[4] Adolor and Pfizer are collaborating in the worldwide development and commercialization of two Delta agonists for pain.[5] Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain.
Adolor has its headquarters in in Exton, PA.
In December 2011, Cubist Pharmaceuticals, Inc. acquired Adolor Corporation.
References
- ^ a b c Adolor (ADLR) annual SEC income statement filing via Wikinvest
- ^ a b Adolor (ADLR) annual SEC balance sheet filing via Wikinvest
- ^ "Company Profile for Adolor Corporation (ADLR)". http://www.zenobank.com/index.php?symbol=ADLR&page=quotesearch. Retrieved 2008-10-20.
- ^ "Adolor narrows loss on falling revenue". The Philadelphia Inquirer. 2008-02-29. http://www.philly.com/inquirer/breaking/business_breaking/20080229_Adolor_narrows_loss_on_falling_revenue.html. Retrieved 2008-03-21.[dead link]
- ^ "Pfizer To Acquire Encysive For About $195 Mln Cash; Plans Late Stage Trial For PAH Therapy". RTT News. 2008-02-20. http://www.rttnews.com/sp/todaystop.asp?date=02/20/2008&item=47. Retrieved 2008-03-21.
External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
Post a question - any question - to the WikiAnswers community:
Copyrights:
Wikipedia on Answers.com
This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article Adolor Corporation.
Read more